MedPath

COSETTE PHARMACEUTICALS, INC.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

1

Active:0
Completed:0

Trial Phases

1 Phases

Phase 4:1

Drug Approvals

58

FDA:58

Drug Approvals

NITROGLYCERIN

Approval Date
Feb 21, 2024
FDA

Griseofulvin

Approval Date
Dec 27, 2023
FDA

PROMETHEGAN

Approval Date
Nov 30, 2023
FDA

PROMETHEGAN

Approval Date
Nov 30, 2023
FDA

HYDROCORTISONE VALERATE

Approval Date
Nov 29, 2023
FDA

Metronidazole

Approval Date
Nov 29, 2023
FDA

Hydrocortisone Valerate

Approval Date
Nov 29, 2023
FDA

Nystatin

Approval Date
Nov 29, 2023
FDA

Tazarotene

Approval Date
Nov 29, 2023
FDA

Mometasone Furoate

Approval Date
Nov 29, 2023
FDA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 4
1 (100.0%)

Single Dose of Vyleesi in Lactating Female Subjects to Measure the Concentration of Bremelanotide in Breast Milk

Phase 4
Not yet recruiting
Conditions
Lactating Mother
Interventions
Drug: Vyleesi (Bremelanotide Injection)
First Posted Date
2025-03-10
Last Posted Date
2025-03-10
Lead Sponsor
Cosette Pharmaceuticals, Inc.
Target Recruit Count
10
Registration Number
NCT06867835

News

No news found
© Copyright 2025. All Rights Reserved by MedPath